Page 4 - கோர் ஒன்று ஆய்வகங்கள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கோர் ஒன்று ஆய்வகங்கள் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கோர் ஒன்று ஆய்வகங்கள் இன்க் Today - Breaking & Trending Today

Core One Labs Inc.: Core One Labs Provides Clarification on Trading Activity


Core One Labs Inc.: Core One Labs Provides Clarification on Trading Activity
Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62, WKN:A2P8K3) (the
Company or
Core One ). This news release is issued at the request of the Investment Industry Regulatory Organization of Canada (
IIROC ) and the Canadian Securities Exchange (
CSE ). Statements made in the news release issued by the Company on May 4, 2021 indicated that the Company had been made aware of potentially manipulative trading activity in its common shares. The news release issued on May 4, 2021 was not reviewed by IIROC or the CSE prior to dissemination, and to date the Company has not filed a formal complaint with any regulatory authority regarding this trading activity. ....

Province Of Ontario , British Columbia , Joel Shacker , While The Company , Company On , Core One Labs Inc , Investment Industry Regulatory Organization Of Canada , Health Canada , Company Or Core , Canadian Securities Exchange , Core One Labs , Investment Industry Regulatory Organization , Capital Markets Modernization Taskforce , Disclaimer Statement , Controlled Drugs , Substances Act , Core One , மாகாணம் ஆஃப் ஆஂடேரியொ , பிரிட்டிஷ் கொலம்பியா , ஜோயல் குலுக்கல் , போது தி நிறுவனம் , நிறுவனம் ஆன் , கோர் ஒன்று ஆய்வகங்கள் இன்க் , முதலீடு தொழில் ஒழுங்குமுறை ஆர்கநைஸேஶந் ஆஃப் கனடா , ஆரோக்கியம் கனடா , நிறுவனம் அல்லது கோர் ,

Core One Labs Provides Clarification on Trading Activity


Core One Labs Provides Clarification on Trading Activity
ACCESSWIRE
VANCOUVER, BC / ACCESSWIRE / May 21, 2021 /
Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62, WKN:A2P8K3) (the
Company or
Core One ). This news release is issued at the request of the Investment Industry Regulatory Organization of Canada (
IIROC ) and the Canadian Securities Exchange (
CSE ). Statements made in the news release issued by the Company on May 4, 2021 indicated that the Company had been made aware of potentially manipulative trading activity in its common shares. The news release issued on May 4, 2021 was not reviewed by IIROC or the CSE prior to dissemination, and to date the Company has not filed a formal complaint with any regulatory authority regarding this trading activity. ....

Province Of Ontario , British Columbia , Joel Shacker , While The Company , Company On , Core One Labs Inc , Investment Industry Regulatory Organization Of Canada , Health Canada , Company Or Core , Canadian Securities Exchange , Core One Labs , Core One , Investment Industry Regulatory Organization , Capital Markets Modernization Taskforce , Disclaimer Statement , Controlled Drugs , Substances Act , United States Wire Group , மாகாணம் ஆஃப் ஆஂடேரியொ , பிரிட்டிஷ் கொலம்பியா , ஜோயல் குலுக்கல் , போது தி நிறுவனம் , நிறுவனம் ஆன் , கோர் ஒன்று ஆய்வகங்கள் இன்க் , முதலீடு தொழில் ஒழுங்குமுறை ஆர்கநைஸேஶந் ஆஃப் கனடா , ஆரோக்கியம் கனடா ,

Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M


The
Multidisciplinary Association for Psychedelic Studies released the results from its Phase 3 trial on MDMA for the treatment of post-traumatic stress disorder. 
The randomized, blinded, Phase 3 trial enrolled 90 patients with severe chronic PTSD who were divided into two groups. 
The first group of 46 participants received three sessions of MDMA-assisted talk therapy, while the control group of 44 people received a placebo as well as the same talk therapy.
Results were measured after 18 weeks. Sixty-seven percent of participants in the MDMA-assisted therapy group no longer qualified for a PTSD diagnosis after the MDMA-assisted therapy sessions versus 32% in the placebo group.
Eighty-eight percent of participants from the MDMA group experienced a clinically significant reduction in symptoms versus 60% in the control group. ....

New York , United States , United Kingdom , San Diego , City Of , San Carlos , Los Angeles , Alex Dominguez , Yaron Conforti , Daniel Carcillo , Braxia Scientific Corp , Multidisciplinary Association For Psychedelic , Wesana Health Go Public , Gilgamesh Pharmaceuticals , Canadian Securities Exchange , Champignon Brands Inc , Venture Exchange , Wesana Health Inc , Novamind Inc , Movers Lab , Department Of State Health Services , Core One Labs Inc , Small Pharma Inc , Field Trip Health Ltd , Akome Biotech Ltd , British Columbia Securities Commission ,